Home
Buchanan Ingersoll & Rooney PC
Edward John Allera
Edward John Allera
Buchanan Ingersoll & Rooney PC
SCT's And Bad Evidence Generation: 4 Solutions To Combat Its Permeation Into The Drug Approval Process
14 Sep 2022 | United States
Legal Innovators Interview Series - The General Counsel At Covis Pharma Discusses The World Of Pharmaceutical Approvals Around The Globe - Corporate Counsel (Podcast)
12 May 2021 | United States
Life Sciences Executive Exchange Series - Webinar Recap
01 Apr 2021 | United States
Operating At Warp Speed: Key Takeaways From COVID-19 Clinical Trials
01 Dec 2020 | United States
Leaders In Life Sciences Key Takeaways
19 Nov 2020 | United States
Key Business And IP Considerations For Furthering Drug Repurposing Programs
21 Sep 2020 | United States
Life Sciences Playbook - Navigating Operational And Regulatory Challenges While Emerging From The COVID-19 Pandemic
22 Jul 2020 | United States
Top 10 Investor Insights On Life Sciences Post-COVID-19
13 Jul 2020 | United States
Increasing Revenue And Decreasing Costs As Life Sciences Companies Emerge From COVID-19
22 May 2020 | United States
Make Your Voice Heard In Washington Amid The COVID-19 Pandemic
30 Apr 2020 | United States
In The Chaos Of COVID-19 Pandemic, What Is "Current" In cGMP?
24 Apr 2020 | United States
FDA's Coronavirus Triage – How Pharma Can Work With The Agency To Tackle A Pandemic
07 Apr 2020 | United States
Clinical Trial Data In The Time Of COVID-19
28 Mar 2020 | United States
EBook: NDA 2.0 – The Changing World Of New Drug Applications And How To Successfully Play In The Middle Ground
07 Feb 2020 | United States
Contact Details
Washington
Email Website
Washington
United States

  © Mondaq® Ltd 1994 - 2024. All Rights Reserved.